Novavax ups its Covid-19 trial enrolment target for the UK, plans a November start for the US.

Having been stalled by manufacturing delays, Novavax aims to start its Phase III Covid-19 vaccine trial in the US and Mexico in November.



With its UK trial having enrolled more than 5,500 participants since its September start, the Maryland-based company plans to increase its target to 15,000 – a 5,000 increase from its initial target as reported cases increase across many parts of Europe. The trial’s interim data is expected during the first quarter of 2021.


With support from the US government through the Operation Warp Speed, the North American leg of the trial targeting 30,000 participants across the US and Mexico is expected to kick off by the end of November. In line with what other vaccine developers have adopted, the US biotech also plans to publish its protocol for the US trial.


Having raised US$2bn in funding, including a US$1.6bn from Operation Warp Speed and US$388m from the Coalition for Epidemic Preparedness (CEPI), Novavax’s Covid-19 vaccine NVX-CoV2373 is one of the most watched candidates as the industry looks to curb the pandemic that continues to wreak havoc across the globe.